Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The last earnings update was 102 days ago. More info.
Add to Portfolio Compare Print
LZ1 Share Price and Events
7 Day Returns
1 Year Returns
LZ1 Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Momenta Pharmaceuticals (LZ1) | 9% | 12.8% | 2.3% | -12.4% | 33.6% | -11.5% |
| DE Biotechs | 3.2% | -3.4% | -1% | -3.7% | 88.2% | 10.3% |
| DE Market | 3% | 2.8% | -0.7% | -12.1% | 11.8% | 4.9% |
1 Year Return vs Industry and Market
- LZ1 underperformed the Biotechs industry which returned -3.7% over the past year.
LZ1 Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Momenta Pharmaceuticals
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Momenta Pharmaceuticals.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 11.2% |
| Perpetual Growth Rate | 10-Year DE Government Bond Rate | 0.2% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year DE Govt Bond Rate | 0.2% |
| Equity Risk Premium | S&P Global | 9.8% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.13 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.127 (1 + (1- 21%) (0%)) |
1.127 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.13 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.127 * 9.77%) |
11.24% |
Discounted Cash Flow Calculation for DB:LZ1 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Momenta Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (USD, Millions) | -120.75 | -142.80 | -145.00 | -2.97 | 243.50 |
| Source | Analyst x4 | Analyst x3 | Analyst x2 | Analyst x3 | Analyst x2 |
|
Present Value Discounted (@ 11.24%) |
-108.54 | -115.39 | -105.32 | -1.94 | 142.92 |
| Present value of next 5 years cash flows | $-188.27 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= $243.50 × (1 + 0.23%) ÷ (11.24% – 0.23%) |
$2,215.29 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= $2,215.29 ÷ (1 + 11.24%)5 |
$1,300.26 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= $-188.27 + $1,300.26 |
$1,111.99 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,111.99 / 98.24 |
$9.39 |
| Calculation | Result | |
|---|---|---|
| Non-primary Listing Adjustment Factor |
1 share in DB:LZ1
represents 0.82968x
of
NasdaqGS:MNTA
(This could be a different class, a depositary receipt, a different currency, or all of these things.) |
0.82968x |
| Value per Share (Listing Adjusted, EUR) |
= Value per Share (USD) x Listing Adjustment Factor
= $ 11.32 x 0.82968 |
€9.39 |
| Value per share (EUR) | From above. | €9.39 |
| Current discount | Discount to share price of
€11.35
= -1 x (€11.35 - €9.39) / €9.39 |
-20.9% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Momenta Pharmaceuticals is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Momenta Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Momenta Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-2.03 |
| NasdaqGS:MNTA Share Price ** | NasdaqGS (2019-02-15) in USD | $13.68 |
| Europe Biotechs Industry PE Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 24.27x |
| Germany Market PE Ratio | Median Figure of 419 Publicly-Listed Companies | 18.21x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Momenta Pharmaceuticals.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:MNTA Share Price ÷ EPS (both in USD) = 13.68 ÷ -2.03 |
-6.75x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Momenta Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
- Momenta Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does
Momenta Pharmaceuticals's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -6.75x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
24.1%per year |
| Europe Biotechs Industry PEG Ratio | Median Figure of 21 Publicly-Listed Biotechs Companies | 1.45x |
| Germany Market PEG Ratio | Median Figure of 276 Publicly-Listed Companies | 1.42x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Momenta Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Momenta Pharmaceuticals's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $3.22 |
| NasdaqGS:MNTA Share Price * | NasdaqGS (2019-02-15) in USD | $13.68 |
| Germany Biotechs Industry PB Ratio | Median Figure of 14 Publicly-Listed Biotechs Companies | 2.39x |
| Germany Market PB Ratio | Median Figure of 566 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:MNTA Share Price ÷ Book Value per Share (both in USD) = 13.68 ÷ 3.22 |
4.25x |
* Primary Listing of Momenta Pharmaceuticals.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Momenta Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
Value checks
We assess Momenta Pharmaceuticals's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Momenta Pharmaceuticals has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
LZ1 Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Momenta Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Momenta Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
- Momenta Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| DB:LZ1 Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 24.1% |
| DB:LZ1 Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 12.3% |
| Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 29.7% |
| Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 25.6% |
| Germany Market Earnings Growth Rate | Market Cap Weighted Average | 9.6% |
| Germany Market Revenue Growth Rate | Market Cap Weighted Average | 4.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 132 | -58 | -64 | 3 |
| 2022-12-31 | 84 | -56 | -62 | 4 |
| 2021-12-31 | 84 | -51 | -42 | 4 |
| 2020-12-31 | 78 | -108 | -77 | 6 |
| 2019-12-31 | 73 | -96 | -72 | 7 |
| 2018-12-31 | 50 | -176 | -213 | 5 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 97 | -161 | -154 |
| 2018-06-30 | 107 | -144 | -137 |
| 2018-03-31 | 117 | -132 | -104 |
| 2017-12-31 | 139 | -30 | -88 |
| 2017-09-30 | 108 | 53 | -60 |
| 2017-06-30 | 114 | 55 | -45 |
| 2017-03-31 | 116 | 57 | -29 |
| 2016-12-31 | 110 | 8 | -21 |
| 2016-09-30 | 98 | -60 | -92 |
| 2016-06-30 | 82 | -36 | -104 |
| 2016-03-31 | 101 | -29 | -85 |
| 2015-12-31 | 90 | -72 | -83 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -1.38 | -1.38 | -1.38 | 1.00 |
| 2022-12-31 | -1.07 | -1.07 | -1.07 | 1.00 |
| 2021-12-31 | -0.79 | -0.79 | -0.79 | 1.00 |
| 2020-12-31 | -0.73 | -0.73 | -0.73 | 1.00 |
| 2019-12-31 | -0.84 | -0.76 | -0.91 | 2.00 |
| 2018-12-31 | -2.71 | -2.70 | -2.71 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -2.03 |
| 2018-06-30 | -1.82 |
| 2018-03-31 | -1.39 |
| 2017-12-31 | -1.20 |
| 2017-09-30 | -0.84 |
| 2017-06-30 | -0.64 |
| 2017-03-31 | -0.42 |
| 2016-12-31 | -0.31 |
| 2016-09-30 | -1.34 |
| 2016-06-30 | -1.53 |
| 2016-03-31 | -1.28 |
| 2015-12-31 | -1.32 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Momenta Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Momenta Pharmaceuticals's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Momenta Pharmaceuticals has a total score of 1/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
LZ1 Past Performance
How has Momenta Pharmaceuticals performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Momenta Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Momenta Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Momenta Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 97.38 | -154.06 | 79.41 | 80.09 |
| 2018-06-30 | 106.58 | -136.95 | 79.67 | 82.01 |
| 2018-03-31 | 117.12 | -103.97 | 79.71 | 79.40 |
| 2017-12-31 | 138.88 | -88.10 | 82.21 | 76.76 |
| 2017-09-30 | 108.47 | -60.32 | 84.55 | 79.64 |
| 2017-06-30 | 113.52 | -44.67 | 79.60 | 78.89 |
| 2017-03-31 | 116.38 | -28.75 | 71.92 | 80.42 |
| 2016-12-31 | 109.62 | -21.00 | 64.47 | 78.71 |
| 2016-09-30 | 97.82 | -91.71 | 60.67 | 78.23 |
| 2016-06-30 | 82.47 | -104.21 | 57.38 | 77.62 |
| 2016-03-31 | 100.94 | -85.45 | 55.81 | 77.67 |
| 2015-12-31 | 89.65 | -83.31 | 48.05 | 73.45 |
| 2015-09-30 | 88.44 | -70.13 | 44.80 | 71.59 |
| 2015-06-30 | 83.98 | -69.18 | 43.45 | 71.29 |
| 2015-03-31 | 50.03 | -93.12 | 41.34 | 69.24 |
| 2014-12-31 | 52.25 | -98.60 | 45.16 | 74.03 |
| 2014-09-30 | 43.82 | -112.68 | 44.89 | 75.39 |
| 2014-06-30 | 45.24 | -108.96 | 42.76 | 74.29 |
| 2014-03-31 | 38.65 | -111.65 | 43.06 | 72.25 |
| 2013-12-31 | 35.47 | -108.41 | 41.06 | 69.75 |
| 2013-09-30 | 35.44 | -96.02 | 39.58 | 66.01 |
| 2013-06-30 | 29.79 | -96.46 | 41.61 | 96.27 |
| 2013-03-31 | 47.30 | -77.78 | 42.44 | 79.40 |
| 2012-12-31 | 63.92 | -58.65 | 43.68 | 62.66 |
| 2012-09-30 | 80.65 | -42.22 | 44.02 | 47.39 |
| 2012-06-30 | 163.49 | 43.94 | 44.51 | |
| 2012-03-31 | 229.12 | 118.37 | 41.36 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Momenta Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Momenta Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Momenta Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Momenta Pharmaceuticals's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Momenta Pharmaceuticals has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
LZ1 Health
How is Momenta Pharmaceuticals's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Momenta Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
- Momenta Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Momenta Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Momenta Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 248.76 | 0.00 | 275.08 |
| 2018-06-30 | 281.69 | 0.00 | 310.83 |
| 2018-03-31 | 334.42 | 0.00 | 323.90 |
| 2017-12-31 | 374.15 | 0.00 | 342.67 |
| 2017-09-30 | 360.51 | 0.00 | 418.79 |
| 2017-06-30 | 386.86 | 0.00 | 446.55 |
| 2017-03-31 | 370.32 | 0.00 | 433.75 |
| 2016-12-31 | 371.91 | 0.00 | 353.15 |
| 2016-09-30 | 325.78 | 0.00 | 308.96 |
| 2016-06-30 | 334.64 | 0.00 | 336.92 |
| 2016-03-31 | 351.48 | 0.00 | 345.79 |
| 2015-12-31 | 369.98 | 0.00 | 350.04 |
| 2015-09-30 | 393.26 | 0.00 | 374.87 |
| 2015-06-30 | 416.64 | 0.00 | 377.17 |
| 2015-03-31 | 216.70 | 0.00 | 198.70 |
| 2014-12-31 | 206.37 | 0.00 | 191.53 |
| 2014-09-30 | 200.36 | 0.00 | 176.46 |
| 2014-06-30 | 225.37 | 0.00 | 202.28 |
| 2014-03-31 | 247.75 | 0.00 | 223.95 |
| 2013-12-31 | 269.84 | 0.00 | 245.68 |
| 2013-09-30 | 295.99 | 0.00 | 275.90 |
| 2013-06-30 | 314.92 | 0.00 | 300.16 |
| 2013-03-31 | 340.05 | 0.00 | 324.20 |
| 2012-12-31 | 360.49 | 0.00 | 340.60 |
| 2012-09-30 | 374.72 | 0.00 | 361.82 |
| 2012-06-30 | 396.31 | 0.00 | 372.31 |
| 2012-03-31 | 402.19 | 0.00 | 382.26 |
- Momenta Pharmaceuticals has no debt.
- Momenta Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Momenta Pharmaceuticals has sufficient cash runway for 1.6 years based on current free cash flow.
- Momenta Pharmaceuticals has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 41.6% each year.
Financial health checks
We assess Momenta Pharmaceuticals's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Momenta Pharmaceuticals has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
LZ1 Dividends
What is Momenta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Momenta Pharmaceuticals
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Momenta Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Momenta Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 0.9% |
| Germany Market Average Dividend Yield | Market Cap Weighted Average of 332 Stocks | 3.1% |
| Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| Germany Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| Germany Top 25% Dividend Yield | 75th Percentile | 4% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
| 2018-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Momenta Pharmaceuticals has not reported any payouts.
- Unable to verify if Momenta Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Momenta Pharmaceuticals's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Momenta Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Momenta Pharmaceuticals has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
LZ1 Management
CEO
| COMPENSATION | $4,784,639 |
| AGE | 58 |
| TENURE AS CEO | 12.4 years |
CEO Bio
Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Director at Momenta Pharmaceuticals Inc. since August 22, 2006. He was Principal Financial Officer and Principal Accounting Officer of Momenta Pharmaceuticals since May 8, 2018 to October 5, 2018. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX and once-daily COPAXONE. He has also overseen the growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications at Momenta Pharmaceuticals. He served as the Board Chairman, Treasurer and Secretary of Generic Pharmaceutical Association until February 22, 2016. Mr. Wheeler served as a Vice President of Chiron Corp. from August 2001 to June 2006. Prior to joining Momenta, he served as the President of Chiron Biopharmaceuticals, a division of Chiron Corp. from August 2001 to June 2006. He was responsible for all aspects of the Biopharmaceuticals business unit, including commercial, research, development and manufacturing. During his tenure at Chiron, he led the restructuring of the business unit to refocus on oncology and infectious disease. Mr. Wheeler served as a Partner and served as a Senior Member of health care practice at The Boston Consulting Group and a key contributor to its practice in hospital strategy, disease management and pharmaceutical capabilities from August 1988 to August 2001. He began his career at Merck & Company, Inc.'s MSDRL research unit. Mr. Wheeler served as a Senior Engineer in process development at Merck's MSDRL research unit. He served as the Leader of Scientist's Network at The Boston Consulting Group. In partnership with Rockefeller Foundation, he has joined Global Alliance for TB Drug Development. He served as a Financial Analyst for Hybritech. He has extensive professional experience in the biotechnology and healthcare industries. Mr. Wheeler served as the Chairman of Avanir Pharmaceuticals, Inc. from May 3, 2007 to January 13, 2015 and GPhA from 2014 to February 2016. He serves as a Director of Association for Accessible Medicines. He has been a Director of Amicus Therapeutics, Inc. since June 10, 2016. Mr. Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his demonstrated expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr. Wheeler serves as a Director of California Healthcare Institute. He serves as a Member of the Chief Executive Officer Roundtable on Cancer, Inc. He also serves on the IBM Life Science Strategic Advisory Council and the Whitehead Institute for Biomedical Research's Board of Associates. He served as a Director of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) until February 22, 2016. Mr. Wheeler served as a Director of Avanir Pharmaceuticals, Inc. from September 27, 2005 to January 13, 2015. In 2011, Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. Mr. Wheeler holds BS and an MS Degree in Chemical Engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania, where he majored in Marketing and Finance.
CEO Compensation
- Craig's compensation has increased whilst company is loss making.
- Craig's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the Momenta Pharmaceuticals management team in years:
- The average tenure for the Momenta Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team
Craig Wheeler
President
$5M
58
12.4 yrs
Ganesh Kaundinya
Co-Founder & Consultant
$2M
51
Santiago Arroyo
Chief Medical Officer & Senior VP of Development
$3M
1.7 yrs
Bruce Leicher
Consultant
$2M
62
0.3 yrs
Scott Storer
Consultant
$569K
0.3 yrs
Michelle Robertson
Principal Financial Officer
51
0.3 yrs
Tony Manning
Chief Scientific Officer
56
0.3 yrs
Sarah Carmody
Senior Director of Investor Relations & Corporate Communications
Alejandra Carvajal
Chief Legal Officer
0.3 yrs
Young Kwon
Chief Business Officer
Board of Directors Tenure
Average tenure and age of the Momenta Pharmaceuticals board of directors in years:
- The tenure for the Momenta Pharmaceuticals board of directors is about average.
Board of Directors
Bruce Downey
Chairman
$273K
71
0.7 yrs
Craig Wheeler
President
$5M
58
12.5 yrs
Liz Stoner
Director
$270K
68
11.3 yrs
Georges Gemayel
Director
$270K
58
3.1 yrs
Corey Fishman
Director
$268K
53
2.4 yrs
Robert Pollock
Member of Regulatory Advisory Board
Thomas Garvey
Member of Regulatory Advisory Board
J. Crout
Member of Regulatory Advisory Board
88
Benito Casu
Member of Scientific Advisory Board
Richard Cooper
Member of Regulatory Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Momenta Pharmaceuticals's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Momenta Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
LZ1 Company Info
Map
Description
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Details
| Name: | Momenta Pharmaceuticals, Inc. |
| LZ1 | |
| Exchange: | DB |
| Founded: | 2001 |
| $1,192,075,604 | |
| 98,241,296 | |
| Website: | http://www.momentapharma.com |
| Address: |
Momenta Pharmaceuticals, Inc. 675 West Kendall Street, Cambridge, Massachusetts, 02142, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | MNTA | Common Stock | Nasdaq Global Select | US | USD | 22. Jun 2004 | |
| DB | LZ1 | Common Stock | Deutsche Boerse AG | DE | EUR | 22. Jun 2004 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/17 20:33 |
| End of day share price update: | 2019/02/15 00:00 |
| Last estimates confirmation: | 2019/01/06 |
| Last earnings filing: | 2018/11/07 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
